CAR-T Therapies

Featured Article
Understanding CAR-T Clinical Trial Enrollment
True or False: Criteria for inclusion and exclusion in clinical trials of chimeric antigen receptor T-cell therapy for hematologic malignancies are highly variable and bring to light the need for a more standardized approach to patient enrollment.
Benefits of CD30 CAR-T Therapy for Multiply Relapsed Enteropathy-Associated T-Cell Lymphoma
In a recent case study, CAR-T therapy targeting the CD30 molecule promoted a durable remission in a patient with multiply relapsed enteropathy-associated T-cell lymphoma after previous allogeneic…
Enrollment Criteria Varies Widely Across CAR-T Therapy Trials
Recent research shows that criteria for inclusion and exclusion in clinical trials of CAR‐T therapy for hematologic malignancies are highly variable and bring to light the need for a more…

Newsfeed

Understanding CAR-T Clinical Trial Enrollment
Benefits of CD30 CAR-T Therapy for Multiply Relapsed Enteropathy-Associated T-Cell Lymphoma
Enrollment Criteria Varies Widely Across CAR-T Therapy Trials
Relapses After CAR-T Therapy Offer Insight for New Strategies
CAR T-Cell Therapy Has a Bright Future for Solid Tumors, Researchers Predict
Study Questions Financial Viability of Inpatient CAR-T Therapy for Lymphoma
Regulating the Use of CAR-T Therapy Outside of the Drug Paradigm
Improved Outcomes Associated With CD19-Specific CAR-T Therapy in CLL Patients
View More

Insights

Regulating the Use of CAR-T Therapy Outside of the Drug Paradigm
Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA Health…
Concerns With Payment, Administration of Car-T Therapies
Gary Goldstein, business manager of the Blood and Marrow Transplant Program at Stanford Health Care, discusses the changes needed for increased CAR-T administration in the outpatient setting as well as commercial and provider concerns about the…
What is CAR-T and How Does it Work?
An interview with Nicole M Trask, PharmD, a clinical consultant pharmacist at UMass Medical School and secretary of the AMCP’s Northeast Regional Affiliate.
Impact of CAR-T on Management of Hematological Malignancies
An interview with Russel J Spjut, PharmD, formulary management clinical pharmacist and consultant at Formulary Intel Consulting.
View More

Interactive Features

Understanding CAR-T Clinical Trial Enrollment
True or False: Criteria for inclusion and exclusion in clinical trials of chimeric antigen receptor T-cell therapy for hematologic malignancies are highly variable and bring to light the need for a more standardized approach to patient enrollment.
Penn Medicine Looks to Improve Outcomes for Solid Tumors With CAR-T
By Julie Gould Podcast Series:  In this episode, Steven Albelda, MD, professor of medicine at the University of Pennsylvania, Pulmonary Division, discusses a $10 million grant that Penn Medicine recently received from the National…
Newly Released Recommendations For Future CAR-T Use
By Julie Gould Podcast Series: In this episode, Elizabeth Budde, MD, PhD, assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, discusses recommendations that were recently created by a…
Concerns With Payment, Administration of CAR-T Therapies
By Zachary Bessette Podcast Series: Gary Goldstein, business manager of the Blood and Marrow Transplant Program at Stanford Health Care, discusses the changes needed for increased CAR-T administration in the outpatient setting as well as…
View More
Back to Top